Cruz HBR
| abstract | Post-market registry to evaluate the safety and efficacy of the Supraflex Cruz™ sirolimus-eluting coronary stent system in the treatment of all-comer patients with coronary artery disease |
| type of project | clinical studies |
| status | ongoing - follow up |
| start of project | 2020 |
| end of project | 2022 |
| study design |
Prospective, multi-center, open-label, single-arm registry designed
to enroll 1200 (800 non-High Bleeding Risk (non-HBR) and 400 HBR) allcomer patients with coronary artery disease in around 25 sites in 3 European countries (Switzerland, Germany & France). Patients will receive at least one Supraflex Cruz™ sirolimus-eluting stent as per current practice and will be followed up for 12 months. |
| responsible person | Dr. Daniel Weilenmann |